Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CBT-004 by Cloudbreak Therapeutics for Unspecified Ophthalmological Disorders: Likelihood of Approval
CBT-004 is under clinical development by Cloudbreak Therapeutics and currently in Phase II for Unspecified Ophthalmological Disorders. According to GlobalData,...